Alan Jacobs, M.D., FAAN is an accomplished and experienced clinical development professional with experience in early- and late-stage therapeutics in Neuroscience and Rare Diseases. Previously, he was Professor of Neurology at Wright State University Boonshoft School of Medicine and remains a Fellow of the American Academy of Neurology. His academic research and clinical pursuits focused on Neuroimmunology and Neurodegenerative Disorders. He joined Genzyme Medical Affairs in 2015. In 2016, he was the sole annual recipient of the Sanofi Circle of Excellence Award in Medical Affairs. In 2017, he became the Global Clinical Lead for Multiple Sclerosis, Head of the Autoimmune Biomarker Group, and Senior Director for Clinical Development in both Multiple Sclerosis and CNS Lysosomal Storage Disorders within Rare Neurology. In 2019, he joined Immunovant as Vice President of Neurology Development leading programs within multiple Neuroscience indications in both CNS Autoimmunity and Neuromuscular Disease. In 2021, he joined Boston Pharmaceuticals as Vice President of Clinical Development where he led integrated clinical development and biomarker plan integration in a host of Neurodegenerative Disorders, created and directed clinical trials, and contributed to business development collaborations. In 2023, he joined Satellos Bioscience as Chief Medical Officer tasked with the creation of a Clinical Development and Medical Affairs Organization. He participated in numerous interactions related to external fundraising and Board presentations.

Dr. Jacobs earned a B.A. in Chemistry from Johns Hopkins University, an M.D. from Mount Sinai School of Medicine, and received Post-Graduate Medical Education at the Johns Hopkins University School of Medicine, Albert Einstein College of Medicine, Mount Sinai School of Medicine, and the Columbia University-Presbyterian Hospital Neurological Institute.